Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study

Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, Potestio L

Clinical, Cosmetic and Investigational Dermatology 2024, 17:1037-1042

Published Date: 7 May 2024